zulvac 8 bovis
zoetis belgium - inaktyvuotas mėlynojo liežuvio ligos virusas, 8 serotipas, štamas btv-8 / bel2006 / 02 - imunologiniai preparatai - galvijai - active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.
zulvac 8 ovis
zoetis belgium sa - inaktyvuotas mėlynojo liežuvio ligos virusas, 8 serotipas, štamas btv-8 / bel2006 / 02 - imunologiniai preparatai - avys - aktyvus avių imunizavimas nuo 1. 5 mėnesių amžiaus viruso užkrėtimo mėlynojo liežuvio viruso 8 serotipo prevencija.
zulvac sbv
zoetis belgium sa - inaktyvuotas schmallenberg virusas, štamas bh80 / 11-4 - immunologicals už bovidae, inaktyvuotos virusinės vakcinos. - cattle; sheep - veiklioji galvijų ir avių imunizacija nuo 3. 5 mėnesių amžiaus, siekiant užkirsti kelią viremijai, susijusiai su schmallenberg viruso infekcija.
cholib
viatris healthcare limited - fenofibrate, simvastatin - dislipidemijos - lipidą keičiančios medžiagos - cholib skiriamas kaip papildoma terapija sergantiems širdies ir kraujagyslių ligų didelės rizikos suaugusiems pacientams, sergantiems dislipidemijos sumažinti trigliceridų ir padidinti dtl-c koncentracija, kai mtl-c koncentracija yra tinkamai kontroliuojama su atitinkamą dozę simvastatinas monoterapija.
trombopriv
via pharma, uab - tirofibanas - koncentratas infuziniam tirpalui - 250 µg/ml - tirofiban
aggrastat
correvio - tirofibanas - koncentratas infuziniam tirpalui - 250 µg/ml - tirofiban
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
cleave®
adama - suspoemulsija - florasulamas + fluroksipiras - herbicidai